

Index

a

- A1298C polymorphism 41–47
- abdominal obesity 211
- acceptable daily intake 92, 93
- acetaldehyde 111
- acrylamide 110
- adaptive fitness 283
- adaptive immune responses 167, 171
- adipocyte hyperplasia 160
- adipocytokines 211
- adiponectin 211, 216
- adipose tissue 211
- adolescence, health determinants 160, 161
- β 2 adrenoreceptor agonists 258
- adult diseases *see* human diseases
- adults, health determinants 160, 161
- aflatoxin B1 92–94, 105, 109, 113, 117
- aging
 - anti-aging modalities 215–217
 - cancer, epigenetic dysregulation 209–218
 - cancer predisposition model 217
 - cancer-prone metabolic phenotype 210–212
 - diseases associated 158
 - DNA hypermethylation during 183, 184
 - epigenetic silencing via DNA methylation 212, 213
 - extrinsic 27
 - health determinants 160, 161
 - inflammatory control of epigenetic regulators 214, 215
 - intrinsic 27
 - malignant cell development 180
 - metabolism-associated genes 181–183
 - nutrition 26–28
 - *see also* life span; neurodegenerative diseases
- agouti viable yellow murine model 136
- air pollution 22, 253, 256, 258
- alcohol
 - aging 27
 - cancer deaths 106
 - carcinogens 111
 - folate metabolism 43
 - MTHFR variants 46
 - NAFLD 56, 57
- allergens/allergies 132, 255, 257
- ALSPAC data set 68, 73, 75
- aluminium 231
- Alzheimer's disease 225–228, 245, 246
 - diet 237, 238
 - environmental factors 231, 232
 - epigenetic dysregulation 247, 248
 - epigenetics 234–236
 - gene expression 249
 - susceptibility genes 229, 230
- amyloid beta (A β) peptides 226, 228, 234, 236
- amyloid precursor protein gene (APP) 226–228, 234–236
- amyotrophic lateral sclerosis 225–228
 - diet 238
 - environmental factors 231, 232
 - sporadic 236, 237
 - susceptibility genes 229, 230
- ancestors' nutrition 71–74, 81, 82, 136
- antiapoptosis 215
- antibiotics 257
- anticancer therapy 141, 142, 145–152
- antioxidants 112, 113, 118, 151, 235
- AP-1 transcriptional complex 148, 149
- Apolipoprotein E (APOE) 229, 231
- aristolochic acid 109
- arsenic 5, 238
- asthma
 - epigenetic mechanisms 253–260
 - fetal basis 256, 257

ATRA 144–149
 attachment theory 79
 attributable risks 267, 275, 276
 5-aza-2'-deoxycytidine 195, 202, 203
 5-azacytidine 202

b

babies *see* newborn
 Bellagio Model of Public Health Genomics 268–271
 benzo[a]pyren 113
 biobanking and biomolecular resources 55
 biobanks
 – background 51, 52
 – disease- and population-oriented 5, 52, 54, 55
 – formats and purpose 52, 53
 – genome-based 270
 – key components and applications 53
 – need for networks 53–55
 – role in gene–environment interactions 51–60
 – *see also* genetic epidemiology
 bioflavonoids 142, 149, 150
 bioinformatics 127, 128, 132, 214, 249
 biological plausibility 77
 biomarkers
 – chemoprevention 204
 – definition 53, 246
 – identification 58
 – neurodegenerative disorders 245–250
 – *see also* epigenetic marks
 birth weight 75, 159, 161, 175, 255
 bisphenol A 21, 237
 bladder cancer 187
 blood cell transcriptome 130, 131
 blood samples, DNA methylation 200
 brain cancer 187
 brain injuries 232
 breast cancer
 – aging 209
 – diet 145
 – enzyme polymorphisms 114–117
 – estrogen receptor gene 148, 212, 213
 – genes methylated 187
 – MTHFR 44, 45
 butyrate 25

c

C677T polymorphism 37, 41–47
 CAG repeat length 228, 229
 calcitriol 145
 caloric restriction 26, 28, 209, 210, 215–217

cancer
 – aging, epigenetic dysregulation 209–218
 – aging predisposition model 217
 – anticancer therapy 141, 142, 145–152
 – caloric restriction 28
 – causes of death 105, 106, 152, 210, 217
 – deaths 158
 – epigenetic progenitor model 200, 201
 – genetic/epigenetic mechanisms 184
 – genetic factors 106, 184
 – HDAC role 189, 190
 – histone modifications 19, 20
 – hypermethylated gene promoters 187, 188
 – hypo and hypermethylation *see* hypermethylation; hypomethylation
 – low birth weight 255
 – metabolic phenotype, cancer-prone 210–212
 – *see also* carcinogenesis; malignancy; promoter hypermethylation
 Cancer and Leukemia Group B 202
 cancer cells
 – DNA methylation 185, 196, 197
 – genetics and epigenetics 180
 – nuclear structure 179
 cancer genome 195
 cancer risk 209
 – enzyme polymorphisms 114–117
 – from genotoxic dietary carcinogens 111, 112
 – MTHFR gene polymorphisms 37, 41–47
 candidate genes *see* gene candidates
 carbon tetrachloride 92
 carcinogenesis
 – hepatocarcinogenesis 90–99
 – multistage concept 89, 90, 91–95
 – *see also* cancer
 carcinogenic potency 107
 carcinogens
 – dietary protection 112–114
 – DNA methylation 89, 96, 97
 – in foods 105–118
 – in plant-derived foods 109–111
 – *see also* genotoxic carcinogens; non-genotoxic carcinogens
 cardiovascular disease
 – caloric restriction 28
 – deaths 72, 158
 – epigenetic inheritance 72, 78, 81, 82
 – low birth weight 255
 – obesity 8

- overweight in childhood 160
- *see also* coronary heart disease
- β-carotene 145
- case-control study design 38
- cases 52
- catechins 142, 149, 150
- catechols 142, 149–151
- causative genes in neurodegenerative diseases 226–231
- cell-specific responses in asthma 259
- cellular aging 27
- chemoprevention 97, 112, 141, 142, 145–152
 - biomarkers 204
- childhood
 - epigenetic inheritance and life span 75
 - growth velocity 69, 70
 - nutritional and environmental effects 20–22
 - overweight 160, 161
 - proband 68
 - *see also* newborn; slow growth period (SGP)
- cholesterol 128, 129
- chromatin
 - DNA methylation interaction 188–190, 196, 197
 - histone modifications 18, 258
 - packaging 14, 15, 255
- chronic noncommunicable diseases 158–162
- cirrhosis 56, 57
- coffee 133, 134, 138
- coffee polyphenols 142, 149, 150
- cohort studies 38
- colon cancer
 - aging 209
 - C677T polymorphism 45, 47
 - DNA methyltransferases 197
 - genes methylated 187
 - MGMT gene 212
- common disease genetic and epigenetic hypothesis 233
- conjugated linoleic acids 25
- control mechanisms
 - epigenetic 169, 170
 - evolutionary need 167, 168
 - RNA silencing 168, 169
- controls 52
- coronary heart disease
 - coffee consumption 133, 134
 - deaths 78
 - etiology 64, 65, 68
 - obesity 161

- prenatal determinants 159
- *see also* cardiovascular disease
- cortisol/cortisone 177
- CpG islands 143, 255
 - during aging 212
 - in cancer cells 185
 - methylation 3, 15–17
 - neurodegenerative disorders 249
- cutaneous T-cell lymphoma 195, 203
- cycasin 110
- cyclooxygenase-2 promoter 258
- cytochrome P450 92, 109
 - CYP1A1 114, 115
 - CYP1A2 133, 134
- cytokine transforming growth factor β1 95
- cytosine methylation pathway 23, 24
- cytotoxic stress 201, 202

d

- dairy products, transcriptome 131
- Data Schema and Harmonization Platform for Epidemiological Research (DataSHaPER) 54
- de novo* methylation 16, 143
- deaths
 - cancer 105, 106, 152, 158, 210, 217
 - cardiovascular and diabetes-related 72, 158
 - from coronary heart disease 78
 - leading causes 68, 158
 - lung cancer 198
- defense mechanisms 167–171
- depression 255
- developmental origins of adult disease 65, 79
- diabetes
 - deaths 72, 158
 - epigenetic inheritance 63, 72, 77, 81, 82
 - epigenetic programming 28
 - inflammatory control 214
 - low birth weight 255
 - NAFLD 56, 57
 - obesity 8, 161
 - pregnancy 175
 - prenatal determinants 159
- Dicer 168–170
- diet
 - age-related diseases 158, 213, 216
 - cancer deaths 105, 106, 152
 - DNA methylation 8, 22–26, 213
 - epigenetic effects 8, 22–28, 282
 - epigenetics in neurodegenerative diseases 237, 238

- genotoxic carcinogens 111, 112
 - pregnancy 24, 159, 256, 257, 282
 - protective effects towards carcinogens 112–114
 - *see also* caloric restriction; foods; nutrition
 - dietary natural compounds 141, 142, 144–152
 - disease clusters 270, 274
 - disease-oriented biobanks 5, 52, 55
 - diseases *see* human diseases; neurodegenerative diseases
 - DNA-adduct measurements 107
 - DNA methylation 15–18, 142–144, 151, 152, 255
 - age-related epigenetic silencing via 212, 213
 - asthma 254, 257–259
 - carcinogens 89, 96, 97
 - chromatin interaction 188–190, 196, 197
 - clinical applications 203, 204
 - CpG islands 3, 15–17
 - diet 8, 22–26, 213
 - epigenetic modification during lifetime 183, 184
 - gene silencing 17, 19
 - methods for detecting 197, 198
 - monitoring in blood samples 200
 - neurodegenerative diseases 236
 - normal and cancer cells 185, 196, 197
 - pathway 17
 - regulation by natural compounds 141, 142, 144–151
 - therapeutic applications of inhibitors 202, 203
 - *see also* hypermethylation; hypomethylation; promoter hypermethylation
 - DNA methyltransferases (DNMTs) 16, 17, 135, 141, 143, 144
 - activities of 181, 183
 - colon cancer 197
 - DNMT1 activity regulation 147–151
 - DNA-reactive carcinogens 112–114
 - DNA-repair genes 114, 116
 - DNA sequencing 129, 130, 133, 174
 - dUMP/dTMP ratio 42
- e**
- ecology 11, 12
 - EGCG 150, 151
 - endocrine disruptors 98, 233
 - endogenous retroviruses 168
 - environmental epigenomics 238, 239
 - environmental health 11
 - environmental influences
 - asthma 253, 254, 256
 - complex diseases 272
 - early life conditions 20–22
 - ecology 11, 12
 - epigenetics, and human diseases 233, 234
 - fetal development 174–176, 282
 - health 158
 - neurodegenerative diseases 231–233, 239
 - pollution and toxins 22
 - *see also* alcohol; diet; foods; gene–environment interactions (GEI); nutrition; smoking
 - enzyme polymorphisms and genotoxic carcinogen metabolism 114–117
 - epidemiology *see* biobanks; genetic epidemiology
 - epigenetic dysregulation
 - aging and cancer 209–218
 - human diseases 233
 - neurodegenerative diseases 236, 247, 248
 - epigenetic health 281–285
 - epigenetic inheritance 77–79, 82
 - future directions 80, 81
 - methodology 65–70
 - patterns 70–77
 - transgenerational models 28, 29
 - epigenetic marks 13, 21, 180, 238
 - in neurodegenerative disorders 245–250
 - *see also* biomarkers
 - epigenetic mechanisms 15–20
 - asthma 253–260
 - cancer 184
 - control mechanisms 169, 170
 - neurodegenerative diseases 230
 - *see also* DNA sequencing; histone modifications; microRNA (miRNA)
 - epigenetic misprogramming 28
 - epigenetic modifications 8, 15, 21, 174, 212
 - DNA methylation 183, 184
 - neurodegenerative diseases 233, 238
 - nutrition 76, 77
 - epigenetic network, metabolism role 181, 182
 - epigenetic plasticity 200, 201
 - epigenetic progenitor model, cancer 200, 201
 - epigenetic reprogramming cycle 23
 - epigenetic risk factors 274
 - epigenetic “signatures” 209, 210, 213
 - epigenetic therapy approach 282

- epigenetics
 - definition 4
 - environment and human diseases 233, 234
 - evolutionary aspects 28, 29
 - food metabolism 7, 8
 - genetics in cancer cells 180
 - neurodegenerative diseases 234–237, 245–248
 - new paradigm 3–5
 - nutri-epigenetics 135–137
 - public health policy 272, 273, 277, 278
- epigenome 14, 15, 135, 233
- epigenomics 246
 - environmental 238, 239
 - public health policy 272, 273
- estrogen receptor (ER) gene 148, 210, 212, 213
- ethics 272, 277, 283, 284
 - nutrition research 137, 138
- ethnicity
 - gene–environment analysis 56, 57
 - MTHFR gene polymorphisms 43
 - study design 38
 - subgroup analysis 40
 - urine metabolite profile 133
- European Community
 - biobank collaboration 55
 - Public Health Genomics European Network (PHGEN) 267, 271, 272, 281
 - *see also* “Health in all Policies”
- evidence base 268, 271, 273, 276, 277
- evolution theory, and self-organization 5
- evolutionary aspects
 - control mechanisms 167, 168
 - epigenetics 28, 29
- extrinsic aging 27

f

- familial forms, neurodegenerative diseases 226–228
- famine 21
- feedforward control loop 63, 72
- fetal basis
 - adult disease 255, 256, 282
 - asthma 256, 267
- fetal development 159, 160
 - environmental influences 174–176, 282
- fetal programming 64
 - epigenetic inheritance 78, 79
- Finnish government 273
- flavones 137, 146

- flavonoids 25, 26
- folate 23, 24, 118, 237–239
 - MTHFR role in metabolism 37, 41–43, 46, 47, 158
- folate-methionine cycle 135
- folic acid 175, 237
- food additives 109–111
- food availability 69
 - adult diseases 63, 81, 82
 - life span 71–74
 - scarcity 26, 28, 63
 - during the slow growth period 76, 77
 - *see also* caloric restriction
- food metabolism, and epigenetics 7, 8
- foods
 - carcinogens 105–118
 - diversity 157, 161, 162
 - functional 118, 137
 - genotoxic carcinogens 106–111
- forest plot 44, 45
- fragile X syndrome 246, 247
- fragile X tremor and ataxia syndrome 246, 247
- free radical theory of development 235
- fumonisin B1 109
- functional foods 118, 137
- fundamental rights 277
- fungi, RNA silencing 170
- fungicides 20, 177, 233

g

- gas chromatography-mass spectrometry 132
- gastrointestinal cancers
 - C677T polymorphism 44–47
 - genes methylated 187
- gene candidates 57, 229, 231
 - epigenetic biomarkers 248, 249
- gene–environment interactions (GEI) 4, 43
 - asthma 254
 - NAFLD development 57, 58
 - role of biobanks 51–60
- gene expression 7, 65, 66
 - diet 141, 142
 - hereditary and epigenetic interactions 13–29
 - neurodegenerative disorders 248, 249
- gene polymorphisms *see* MTHFR gene polymorphisms; single nucleotide polymorphisms (SNPs); tandem repeat polymorphisms
- gene silencing 184, 188
 - age-related via DNA methylation 212, 213

- DNA methylation 17, 19
 - *see also* RNA silencing
 - General Systems Theory 29
 - generations
 - epigenetic inheritance studies 66–68
 - intergenerational effects 161, 162
 - proband 66–68, 75, 82
 - *see also* transgenerational effects;
 - transgenerational responses
 - genetic and epigenetic plasticity 200, 201
 - genetic association studies
 - MTHFR gene polymorphisms 44–47
 - population-based 37–41
 - genetic epidemiology
 - definition and goals 37, 38
 - Human Genome Epidemiology Network 40, 41
 - Mendelian randomization approach 41
 - meta-analysis 39, 40
 - study designs 38
 - *see also* biobanks
 - genetic modifiers 51, 57
 - genetic selection 76
 - genetics
 - asthma 254
 - cancer cells 180
 - cancer incidence 106, 184
 - genistein 144–147, 149, 237
 - genome *see* cancer genome; epigenome; human genome
 - genome-wide association studies (GWAS) 3, 4, 14
 - genomic biomarkers 246
 - genomic imprinting 63, 72, 77
 - genomics 128
 - nutrition research 129, 130
 - population genomics data 54
 - public health genomics 267, 278
 - genotoxic carcinogens 89–92, 99
 - dietary 111, 112
 - epigenetic effects 96, 97
 - foods 106–111
 - non-parenchymal liver cells 97, 98
 - polymorphism affecting metabolism 114–117
 - genotypes
 - combinations, and cancer risk 114, 116, 117
 - thrifty 28
 - glucocorticoids 176, 177, 258
 - glutathione 216, 235
 - glycidamide 110
 - growth velocity, childhood 69, 70
 - gynaecology 173–177
- ## h
- haplotype blocks 133
 - HapMap 13, 14, 269
 - harmonized standard operating procedures 54
 - harvests, quality 67, 69, 71
 - HDACs *see* histone deacetylases (HDACs)
 - health
 - environmental 11
 - epigenetic 281–285
 - inheritance 268
 - nutrition 7–9
 - population health improvements 269
 - prerequisites 157
 - transgenerational effects 67
 - health care 268
 - health determinants, during life 147–162
 - Health Genome Concept 118
 - health impact assessment 271
 - “Health in all Policies” 272–274
 - attributable risks 275, 276
 - limits in genomics and epigenetics 277, 278
 - health needs assessment 271
 - health promotion 157, 162
 - health technology assessment (HTA) 271, 276, 277
 - hematopoietic malignancies 186, 187
 - hepatocarcinogenesis 90–99
 - hepatocellular carcinomas 56, 57, 109
 - hereditary dispositions 13, 14
 - herpes viruses 171
 - heterochromatin 196
 - heterocyclic aromatic amines (HAAs) 105, 108–110, 113, 117
 - high birth weight 159
 - high pressure liquid chromatography 132
 - histone acetylation 19, 181, 258
 - histone code 19
 - histone deacetylases (HDACs) 17, 19, 188–190
 - asthma 258, 259
 - cancer 189, 190
 - dietary compounds, effect 25, 152
 - inhibitors 248
 - histone methyltransferases (HATs) 17, 19
 - histone modifications 18–20, 24, 25, 255
 - asthma 258
 - cancer 19, 20
 - HIV, defense mechanisms acting 167, 170
 - homocysteine 23, 24, 42, 43, 237, 238, 248

human diseases

- developmental origins 65, 79
- epigenetics, environment 233, 234
- fetal basis 255, 256, 282
- public health issues 272
- susceptibility genes 270
- transgenerational explanations 63, 64, 81, 82
- *see also* neurodegenerative diseases

human epigenome *see* epigenome

human genome 38, 39, 129

- biobanks 270
- whole-genome association studies 231

Human Genome Epidemiology Network 40, 41

Human Genome Organization 127, 129

Human Genome Project 13, 127, 129, 267, 269

human hepatocellular carcinoma 96

human hepatoma cell line HCC-1.2 95

Human Metabolome Database 132

human microbiome 130

Human Relevance Framework Concept 94

Huntington's disease 226, 228, 229, 245, 246

- epigenetic dysregulation 247, 248
- epigenetics 235
- gene expression 249

hyperlipidemia 128, 129

hypermethylation

- aging 183, 184
- aging and cancer 210
- cancer 4, 8, 9, 142–144, 146, 151
- cancer cells 185
- prostate cancer 213
- *see also* DNA methylation; promoter hypermethylation

hypertension 68, 161, 175

hypomethylation and cancer 4, 8, 9, 42, 142

i

ideal study design 66, 67

identical (monozygotic) twins 78, 136, 233

immune competent cells 168, 171

immune responses

- adaptive 167, 171
- T cell 257, 258

immune system 171

- epigenetic mechanisms 256
- nutrition 26

immunoglobulin E 257

improvement in population health 269

in silico experiments 128

in vitro fertilization 176

“indication” 277

individual freedom 272

infancy *see* childhood; newborn

inflammation

- aging and cancer 209–211, 213
- diet 26
- hepatocarcinogenesis 97
- proinflammatory response 254

inflammatory control, age-related epigenetic regulators 214, 215

influenza A virus 170

inheritance

- health and disease 268
- hereditary dispositions 13, 14
- neurodegenerative disorders 246, 247
- *see also* epigenetic inheritance

“initiated” cells 89–93, 95, 97, 98

insecticides 232

insulin-like growth factor 182

insulin resistance

- aging and cancer 209, 211, 214
- pregnancy 175

interferon system 170

intergenerational effects 161, 162

interleukin 8 26

international collaboration in biobanks 54, 55

International HapMap Project 13, 14, 269

intestinal microflora 130, 159

intrauterine growth retardation 159, 161

intrauterine stress 177

intrinsic aging 27

Inuit populations 5

isochor maps 15

isogenic line 66

k

knowledge generation 269, 270

Kupffer cells 98, 99

l

latent early-life association regulation model 235

lead exposure 231, 236, 239

legislation 272–274, 277, 278

- attributable risks 275, 276

leptin 211

leukemias

- acute myeloid 186, 202
- lymphoid 186

life span

- epigenetic inheritance and childhood circumstances 75

- epigenetic modification by DNA methylation 183, 184
- food scarcity 26, 28, 63
- health determinants 157–162
- interactions throughout 161
- paternal ancestors' nutrition 71–74, 81, 82
- *see also* adolescence; aging; childhood
- d-limonene 110
- lineage priming 171
- lipokines 209, 211
- lipoproteins 128, 129
- liquid chromatography-mass spectrometry 132
- Lisbon Treaty 276
- longevity *see* aging; life span
- low birth weight 75, 159, 161, 175, 255
- lung cancer 22
 - diagnostic tools 195
 - genes methylated 187
 - individualization of therapy 203, 204
 - paradigm 198–200
 - therapeutic inhibitors 202
- lymphoid leukemia 186
- lymphoma 186, 195

m

- malignancy
 - aging 180
 - genetic and epigenetic factors 27
 - hematopoietic 186, 187
 - *see also* cancer; carcinogenesis
- mammals, RNA silencing 170
- manganese 231
- margin of exposure concept 92
- mass spectrometry 132
- MDS *see* myelodysplastic syndrome
- meat, cooking methods 108
- Mendelian randomization approach 41
- Mendelian traits 226, 228
- mercury 231
- meta-analyses
 - definition 39
 - genetic association studies 37–41
 - MTHFR gene polymorphisms 44–47
- metabolic programming 79
- metabolic syndrome 209
 - epigenetic programming 28
 - non-alcoholic fatty liver disease 56, 58
- metabolism
 - aging 210–212
 - folate metabolism 37, 41–43, 46, 47, 158
 - food metabolism 7, 8
 - genotoxic carcinogens 114–117
- metabolome analysis 59

- metabolomics 128
 - nutrition research 132, 133
- metallothionein proteins 237
- metals, neurodegenerative diseases 231, 232, 236, 239
- methionine 175, 181, 237
 - folate-methionine cycle 135
 - s-adenosylmethionine 97, 125, 143, 237
- methionine restriction 210, 215–217
- methyl-CpG-binding domains 17
- methylation *see* DNA methylation; hypermethylation; hypomethylation; promoter hypermethylation
- methylation-specific PCR 197, 198
- methylome 236
- MGMT gene 212
- microarray analysis 59, 130
- microenvironment, hepatic 97, 98
- microRNA (miRNA) 20, 168–170, 255
- mitochondrial efficiency 216
- mitochondrial superoxide dismutase (MnSOD) 24
- mobile elements 168
- mode of action concept 94, 95
- modifiable risks 275, 276
- molecular nutrition research 127–129
- mortality *see* deaths
- motor neuron disease *see* amyotrophic lateral sclerosis
- MTHFR gene polymorphisms 37, 41–47, 158, 213
- multifactorial disorders 226
- multiple inheritance systems 80
- multiple myeloma 186
- mycotoxins 109
- myelodysplastic syndrome (MDS) 181–183, 186, 195, 202
- myeloid leukemias 186, 202
- myeloma, multiple 186
- myricetin 150, 151

n

- NAFLD *see* non-alcoholic fatty liver disease (NAFLD)
- national task forces 271
- natural compounds and DNA methylation 141, 42, 144–152
- neoplasia, development 90, 91
- nephrones 175, 176
- neurodegenerative diseases 225, 226
 - caloric restriction and 28
 - causative and susceptibility genes 226–231
 - environmental factors 231–233, 239
 - epigenetic markers 245–250

- epigenetic role of diet 237, 238
- epigenetics 234–237, 247, 248
- neuromelanin 226
- neurotoxins 232, 238
- newborn
 - birth weight 75, 159, 161, 175, 255
 - overfeeding 175
 - postnatal development 159, 160
 - *see also* fetal development
- NF- κ B *see* nuclear factor kappa B (NF- κ B)
- nitrosamines 105, 107, 108, 113, 117
- no-threshold concept 89, 90, 92, 98
- non-alcoholic fatty liver disease (NAFLD)
 - 51, 55–59
 - gene–environment risk factors 57
 - non-communicable diseases, chronic 158–162
- non-genotoxic carcinogens 89–93, 99
 - epigenetic effects 96, 97
 - non-parenchymal liver cells 97, 98
- non-modifiable risks 275, 276
- non-parenchymal liver cells 97, 98
- non-small cell lung cancers (NSCLC)
 - 198–200, 202
- Nrf2 transcriptional factor 112
- nuclear factor kappa B (NF- κ B) 209–211, 214–217
- nuclear magnetic resonance 132
- nuclear structure in a cancer cell 179
- nutri-epigenetics 135–137
- nutrigenetics 133, 134, 158, 237
- nutrigenomics 127, 129–133
- nutrition
 - aging 26–28
 - ancestors’ 71–74, 81, 82, 136
 - early life conditions 20–22
 - epigenetic modification of 76, 77
 - health 7–9
 - immune system 26
 - infancy and childhood 160
 - life-stage 159
 - during the slow growth period 63, 67, 72, 76, 77, 81, 82, 136
 - undernutrition 26, 28, 63
 - *see also* caloric restriction; diet; food availability; foods
- nutrition research
 - ethics and socio-economics 137, 138
 - genomics 129, 130
 - metabolomics 132, 133
 - molecular 127–129
 - proteomics 131, 132
 - transcriptomics 130, 131
- nutritional systems biology 137

o

- obesity 8
 - childhood/adolescence 160, 161
 - deaths from cancer 217
 - epigenetic programming 28
 - inflammatory control 214
 - intergenerational effects 161
 - maternal diet 282
 - NAFLD 56, 57
 - visceral/abdominal 211
 - *see also* overweight
- ochratoxin A 109, 113
- older people *see* aging
- oncogenes 184
- one-carbon metabolic pathway 135
- ornithine transcarbamylase gene 236
- osteoporosis 28, 175, 255
- ovarian cancer 187
- overfeeding, premature babies 175
- Överkalix cohorts of 1890, 1905 and 1920
 - 67, 68, 73, 75
- overweight 8
 - cancer risk 111, 112
 - childhood/adolescence 160, 161
 - deaths from cancer 217
 - *see also* obesity
- oxidative stress 214–216, 234, 235

p

- p*16 gene 199
- p21^{WAF1/CIP1} 147, 148
- p53 protein 94, 109
- 2D-PAGE 132
- PAHs *see* polycyclic aromatic hydrocarbons (PAHs)
- Parkinson’s disease 225–228, 245, 246
 - environmental factors 231, 232
 - epigenetic dysregulation 247, 248
 - gene expression 249
 - susceptibility genes 229, 230
- paternal ancestors’ nutrition 71–74, 81, 82
- paternal smoking 75
- patulin 113
- peroxisome proliferation 94, 97
- peroxisome proliferator-activated receptors 21, 211
- persistent organic pollutants 5
- pesticides 231, 232
- pharmacogenomics 127, 128
- phase I enzymes 114
- phase II enzymes 112, 114
- phenotype, cancer prone, aging 210–212
- phenotypic data 54

- phthalates 94
 - phytoestrogens 144–149
 - plant-derived foods
 - additives and carcinogens 109–111
 - protective effects 112, 113
 - plants, RNA silencing 169, 170
 - pollution
 - air pollution 22, 253, 256, 258
 - persistent organic pollutants 5
 - polycyclic aromatic hydrocarbons (PAHs) 105, 107, 113, 117
 - enzyme polymorphisms 114
 - polymorphisms *see* MTHFR gene
 - polymorphisms; single nucleotide
 - polymorphisms (SNPs); tandem repeat
 - polymorphisms
 - polyphenols 141, 142, 145, 146, 151
 - catechol-containing 149–151
 - pooled analysis 39, 46
 - population-based biobanks 5, 52, 54, 55
 - population-based genetic association studies 37–41
 - population genomics data 54
 - population stratification 38, 40
 - postnatal development 159, 160
 - precautionary principle 277
 - pregnancy
 - ALSPAC data set 68
 - epigenetic changes 175, 176
 - maternal diet 24, 159, 256, 257, 282
 - paternal smoking 75
 - premature babies *see* newborn
 - prenatal development *see* fetal development
 - preneoplastic (initiated) cells 89–93, 95, 97, 98
 - presenilins 227, 228, 234
 - presymptomatic phase 245
 - prevention programs
 - individualized strategies 29, 268, 269
 - risk factors 64, 158
 - proactive approach 282
 - proband generations 66–68, 75, 82
 - proinflammatory response 254
 - proliferating cell nuclear antigen 147
 - promoter hypermethylation 22, 143, 144, 146, 151
 - cancers 187, 188, 212
 - hematopoietic malignancies 186, 187
 - prostate cancer
 - aging 209
 - genes methylated 187, 213
 - protective factors
 - complex diseases 272
 - dietary 112–114
 - proteomics 128, 246
 - nutrition research 131, 132
 - public health challenges
 - neurodegenerative diseases 245
 - responding 282, 283
 - public health expenditure 284
 - Public Health Genomics 267–278
 - Bellagio Model 268–271
 - definition 271
 - epigenetics/epigenomics 272
 - risk 274–276
 - Public Health Genomics European Network (PHGEN) 267, 271, 272, 281
 - Public Health Genomics Foundation 281
 - public health policy 272–278
 - epigenetic health and responsibility 281–285
 - Public Health Trias 270
 - Public Population Project in Genomics 54
 - publication bias 39, 40
 - pyrethroid insecticides 232
- r**
- RASSF1A gene 199
 - rat liver models 91–97
 - Rb/E2F pathway 147, 148
 - reactive oxygen species 91, 92, 112, 113, 214–216, 234, 235
 - real-time quantitative PCR 198
 - regulations *see* legislation
 - relative risks 267, 274
 - renal cancer 187
 - reproductive medicine 173–177
 - reprogramming cycle, epigenetic 23
 - response 281
 - responsibility 281–285
 - resveratrol 144–149, 216
 - retinoic acid 144, 145
 - retroviruses, endogenous 168
 - risk assessment
 - lung cancer 204
 - toxicological 90, 91
 - risk factors
 - attributable and relative 267, 274–276
 - complex diseases 272, 274
 - coronary heart disease 64, 65
 - epigenetic 274
 - hepatocarcinogenesis 92
 - life cycle 157–159, 161
 - NAFLD development 56, 57
 - neurodegenerative diseases 230–232
 - public health policy 275
 - responding 282
 - *see also* cancer risk

risk regulation 274, 275
 RNA silencing 167
 – control 168, 169
 – fungi 170
 – mammals 170
 – plants 169, 170
 – *see also* gene silencing

S

s-adenosylmethionine (SAM) 97, 125, 143, 237
 saccharin 110
 safety evaluation
 – genotoxic chemicals 97, 98
 – tumor promotion 89, 90, 93, 94
 salicylates 214
 secretases 226–228, 234, 235
 self-organization, and evolution theory 5
 senile plaques 226, 228, 247
 sex chromosomes, and epigenetic inheritance 73–75, 77
 short-chain fatty acids 25
 short interfering RNAs 169, 170
 single nucleotide polymorphisms (SNPs) 13, 14, 39
 – cancer risk 114
 – nutrigenetics 133
 – in whole-genome association studies 231
 sirtuins 26, 28, 209, 216, 217
 slow growth period (SGP) 70, 81, 82
 – male 73
 – nutrition 63, 67, 72, 76, 77, 136
 small cell lung cancers 199
 smoking 22
 – asthma 254, 256
 – folate metabolism 43
 – intergenerational effects 161
 – lung cancer 198, 199
 – nitrosamines 108
 – paternal and pregnancy outcome 75
 SNPs *see* single nucleotide polymorphisms
 soccer players 232
 social context, transgenerational responses 70, 71
 socio-economics, nutrition research 137, 138
 spices 110, 111
 sporadic amyotrophic lateral sclerosis 236, 237
 sporadic forms, neurodegenerative diseases 226, 229
 stakeholders 138, 268, 278
 steatohepatitis 56–58
 steatosis 56–58
 stress response 283

stroke 28
 susceptibility, diseases, epigenetics, and the environment 233, 234
 susceptibility genes 51, 57
 – neurodegenerative diseases 226–231
 – public health 270
 systems biology 128, 137, 269

T

T cell immune responses 257, 258
 tamoxifen 96
 tandem repeat polymorphisms 134
 tea catechins 142, 149, 150
 6-thioguanine 201
 thrifty genotype 28
 “Together for Health” 273
 transcription, DNA methylation and chromatin 196, 197
 transcriptome 130, 131
 transcriptomics 128, 246
 – neurodegeneration 249
 – nutrition research 130, 131
 transgenerational effects
 – adult diseases 63, 64
 – epigenetic inheritance 28, 29
 – on human health 67
 transgenerational responses
 – ancestors’ nutrition 71, 81, 136
 – asthma 256, 257
 – nutrition during slow growth period 72, 76, 81, 82, 136
 – paternal ancestors’ nutrition 71–74, 81, 82
 – social context 70, 71
 transitions, concept 11, 12
 translational research 267, 276
 trichostatin A 203
 trichotecenes 109
 tumor initiation 91, 92
 – cellular and molecular mechanisms 93–95
 tumor progression 92, 93
 tumor promotion 89, 90, 92, 93
 – cellular and molecular mechanisms 93–95
 – *see also* non-genotoxic carcinogens
 tumor suppressor genes 181, 184, 188
 – lung cancer 199

U

undernutrition and life span 26, 28, 63
 urine metabolite profile 133
 US National Office of Public Health Genomics 281
 uterine cancer 187

v

valproic acid 203
vegans 24
vegetarians 24
vinclozolin 20, 233
viral infections 167–171
visceral/abdominal obesity 211
vitamin B₁₂ 23, 24, 175, 237–239

vitamin D₃ 144–149

vitamins 141, 144–149, 151

vorinostat 195, 203

w

Waddington 3, 4

whole-genome association studies
231